TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03016819: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Sponsor: Advenchen Laboratories, LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 325 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT03016819 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03016819 Rescue Dossier →